Mark Cuban Says Cutting PBM Fees Won't Reduce Pharmaceutical R&D Funding: 'Manufacturers Can Sell To Us For More'
In a strong rebuttal to concerns over pharmaceutical innovation, billionaire Mark Cuban, co-founder of Cost Plus Drugs and Shark Tank fame, argued that slashing pharmacy benefit manager (PBM) fees could paradoxically increase research and development (RD) funding by allowing manufacturers to earn more.
Benzinga ·